Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 81

1.

Safety and immunogenicity of a novel recombinant subunit respiratory syncytial virus vaccine (BBG2Na) in healthy young adults.

Power UF, Nguyen TN, Rietveld E, de Swart RL, Groen J, Osterhaus AD, de Groot R, Corvaia N, Beck A, Bouveret-Le-Cam N, Bonnefoy JY.

J Infect Dis. 2001 Dec 1;184(11):1456-60. Epub 2001 Nov 13.

PMID:
11709789
2.

Induction of protective immunity in rodents by vaccination with a prokaryotically expressed recombinant fusion protein containing a respiratory syncytial virus G protein fragment.

Power UF, Plotnicky-Gilquin H, Huss T, Robert A, Trudel M, Ståhl S, Uhlén M, Nguyen TN, Binz H.

Virology. 1997 Apr 14;230(2):155-66.

3.

Passive transfer of serum antibodies induced by BBG2Na, a subunit vaccine, in the elderly protects SCID mouse lungs against respiratory syncytial virus challenge.

Plotnicky-Gilquin H, Cyblat-Chanal D, Goetsch L, Lacheny C, Libon C, Champion T, Beck A, Pasche H, Nguyen TN, Bonnefoy JY, Bouveret-le-Cam N, Corvaïa N.

Virology. 2002 Nov 10;303(1):130-7.

4.

Influence of administration dose and route on the immunogenicity and protective efficacy of BBG2Na, a recombinant respiratory syncytial virus subunit vaccine candidate.

Goetsch L, Plotnicky-Gilquin H, Champion T, Beck A, Corvaïa N, Stâhl S, Bonnefoy JY, Nguyen TN, Power UF.

Vaccine. 2000 Jun 1;18(24):2735-42.

PMID:
10781861
5.

A dose-ranging study of a subunit Respiratory Syncytial Virus subtype A vaccine with and without aluminum phosphate adjuvantation in adults > or =65 years of age.

Langley JM, Sales V, McGeer A, Guasparini R, Predy G, Meekison W, Li M, Capellan J, Wang E.

Vaccine. 2009 Sep 25;27(42):5913-9. doi: 10.1016/j.vaccine.2009.07.038. Epub 2009 Aug 3.

PMID:
19651171
6.

Influence of live respiratory syncytial virus priming on the immune response generated by a recombinant vaccine candidate, BBG2Na.

Goestch L, Plotnicky-Gilquin H, Champion T, Beck A, Haeuw JF, Nguyen T, Bonnefoy JY, Corvaïa N.

Vaccine. 2000 Jun 1;18(24):2648-55.

PMID:
10781850
7.
8.

Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants.

Karron RA, Wright PF, Belshe RB, Thumar B, Casey R, Newman F, Polack FP, Randolph VB, Deatly A, Hackell J, Gruber W, Murphy BR, Collins PL.

J Infect Dis. 2005 Apr 1;191(7):1093-104. Epub 2005 Mar 1.

PMID:
15747245
9.

Respiratory syncytial virus vaccine: a systematic overview with emphasis on respiratory syncytial virus subunit vaccines.

Simoes EA, Tan DH, Ohlsson A, Sales V, Wang EE.

Vaccine. 2001 Dec 12;20(5-6):954-60.

PMID:
11738763
10.

Protective immunity against respiratory syncytial virus in early life after murine maternal or neonatal vaccination with the recombinant G fusion protein BBG2Na.

Brandt C, Power UF, Plotnicky-Gilquin H, Huss T, Nguyen T, Lambert PH, Binz H, Siegrist CA.

J Infect Dis. 1997 Oct;176(4):884-91.

PMID:
9333145
11.

BBG2Na an RSV subunit vaccine candidate intramuscularly injected to human confers protection against viral challenge after nasal immunization in mice.

Goetsch L, Plotnicky-Gilquin H, Aubry JP, De-Lys P, Haeuw JF, Bonnefoy JY, Nguyen NT, Corvaïa N, Velin D.

Vaccine. 2001 Jul 16;19(28-29):4036-42.

PMID:
11427280
12.
13.

Evaluation of BBG2Na in infant macaques: specific immune responses after vaccination and RSV challenge.

de Waal L, Power UF, Yüksel S, van Amerongen G, Nguyen TN, Niesters HG, de Swart RL, Osterhaus AD.

Vaccine. 2004 Feb 25;22(8):915-22.

PMID:
15161068
14.

Protective efficacy against respiratory syncytial virus following murine neonatal immunization with BBG2Na vaccine: influence of adjuvants and maternal antibodies.

Siegrist CA, Plotnicky-Gilquin H, Córdova M, Berney M, Bonnefoy JY, Nguyen TN, Lambert PH, Power UF.

J Infect Dis. 1999 Jun;179(6):1326-33.

PMID:
10228051
15.

Evaluation of the live attenuated cpts 248/404 RSV vaccine in combination with a subunit RSV vaccine (PFP-2) in healthy young and older adults.

Gonzalez IM, Karron RA, Eichelberger M, Walsh EE, Delagarza VW, Bennett R, Chanock RM, Murphy BR, Clements-Mann ML, Falsey AR.

Vaccine. 2000 Mar 6;18(17):1763-72.

PMID:
10699324
16.

Long-lasting balanced immunity and protective efficacy against respiratory syncytial virus in mice induced by a recombinant protein G1F/M2.

Zeng R, Qi X, Gong W, Mei X, Wei L, Ma C, Yin X.

Vaccine. 2007 Oct 16;25(42):7422-8. Epub 2007 Aug 23.

PMID:
17850930
17.

Identification and characterisation of multiple linear B cell protectopes in the respiratory syncytial virus G protein.

Power UF, Plotnicky-Gilquin H, Goetsch L, Champion T, Beck A, Haeuw JF, Nguyen TN, Bonnefoy JY, Corvaïa N.

Vaccine. 2001 Mar 21;19(17-19):2345-51.

PMID:
11257359
18.

Pathogenesis of RSV lower respiratory tract infection: implications for vaccine development.

Brandenburg AH, Neijens HJ, Osterhaus AD.

Vaccine. 2001 Apr 6;19(20-22):2769-82. Review.

PMID:
11282187
19.

Vaccination with recombinant modified vaccinia virus Ankara expressing bovine respiratory syncytial virus (bRSV) proteins protects calves against RSV challenge.

Antonis AF, van der Most RG, Suezer Y, Stockhofe-Zurwieden N, Daus F, Sutter G, Schrijver RS.

Vaccine. 2007 Jun 15;25(25):4818-27. Epub 2007 Apr 20.

PMID:
17499893
20.

DDA adjuvant induces a mixed Th1/Th2 immune response when associated with BBG2Na, a respiratory syncytial virus potential vaccine.

Klinguer-Hamour C, Libon C, Plotnicky-Gilquin H, Bussat MC, Revy L, Nguyen T, Bonnefoy JY, Corvaïa N, Beck A.

Vaccine. 2002 Jun 21;20(21-22):2743-51.

PMID:
12034101

Supplemental Content

Support Center